Vivek Subbiah/LinkedIn
May 31, 2025, 03:35
Vivek Subbiah: Delighted to share my commentary on tissue-agnostic cancer therapies
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Hot off the press!
Delighted to share with the world my commentary in the journal Nature Communications perfectly timed for American Society of Clinical Oncology (ASCO) annual meeting!
“Tissue-agnostic cancer therapies: promise, reality, and the path forward”
Diving deep into where we are and where we’re headed with these treatments.
What’s your take on molecular vs. anatomical cancer classification? Drop your thoughts below!
Open access free link.”
You can find more posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:36
Jun 8, 2025, 10:14
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53